Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Production

    Nature custom video - How to beat a brain-eating amoeba

    A decade-long fight against a brain-eating amoeba

    Our Nature Custom Media team recently took on an ambitious project: producing a video that spanned two continents, covered a decade of medical progress, and navigated regulatory hurdles.

    Springer Nature

    - PMLiVE

    GSK shares positive phase 3 results for long-acting biologic in severe asthma

    Depemokimab is designed to allow for six-month dosing intervals for patients with the lung condition

    - PMLiVE

    GSK’s long-acting biologic shown to reduce severe asthma attacks in phase 3 studies

    Approximately 200,000 people in the UK have severe cases of the lung condition

    - PMLiVE

    FDA approves Alvotech and Teva’s Simlandi as interchangeable Humira biosimilar

    Simlandi is approved to treat multiple indications, including rheumatoid arthritis and Crohn’s disease

    Top 10 benefits of virtual advisory boards: Increased Engagement and Insights

    #2. Increased Advisor Engagement and Quality and Quantity of Insights

    Impetus Digital

    - PMLiVE

    AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma

    An estimated 98,000 patients with severe uncontrolled asthma may be eligible for the new treatment

    - PMLiVE

    AstraZeneca’s severe asthma treatment approved in EU for self-administration

    Most healthcare providers, patients and caregivers are able to successfully use the pre-filled pen

    - PMLiVE

    Teva and Allergan finalise terms of US opioid settlements worth $6.6bn combined

    Nearly 500,000 died from an opioid overdose between 1999 and 2019

    - PMLiVE

    Proving the power of a positive mindset to help fix all ills

    There’s a huge amount of fear around health conditions and disease – in fact according to Harvard Medical School, health anxiety affects 12% of adults. We wanted to put a...

    Create Health

    - PMLiVE

    AstraZeneca’s Tezspire receives MHRA approval as add-on treatment for severe asthma

    Tezspire demonstrated reduced annualised rate of asthma exacerbations

    - PMLiVE

    AstraZeneca’s Tezspire receives EC approval as severe asthma add-on treatment

    Tezspire demonstrated superiority across every primary and key secondary endpoint compared to placebo

    - PMLiVE

    AstraZeneca’s Tezspire recommended for approval in the EU by CHMP

    The recommendation is for the treatment of severe asthma as an add-on therapy for patients 12 years and above

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links